Alkermes plc (ALKS)
NASDAQ:ALKS
Want to see ALKS full AI Analyst Report?
ALKS Stock Chart & Stats
$34.53
-$0.20(-0.70%)
At close: 4:00 PM EST
$34.53
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $53.69
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.26M
Market Cap
$8.81B
Enterprise Value$8.65B
Total Cash (Recent Filing)$511.86M
Total Debt (Recent Filing)$1.58B
Price to Earnings (P/E)56.8
Beta0.80
Next Earnings
Jul 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding166,675,810
10 Day Avg. Volume2,296,959
30 Day Avg. Volume2,262,605
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue5.54
Enterprise Value/Gross Profit6.39
Enterprise Value/Ebitda31.29
Forecast
1Y Price Target
$50.20Price Target Upside45.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$1.81B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Positive Cash GenerationVery high gross margins (~85–86% TTM) and positive operating (~$256M) and free cash flow (~$222M) indicate durable product profitability and internal funding capacity. This supports continued R&D, commercialization and debt service without relying solely on external financing.
Proprietary Product Revenue Momentum And LUMRYZ LaunchConsistent, broad-based topline growth—proprietary sales rose 38% YoY and LUMRYZ contributed meaningful early sales and patient ramps—improves revenue diversification and visibility, making near-term commercial cash flows more predictable for operations and investment planning.
Advancing Orexin Pipeline With Regulatory IncentivesOrphan designations and active Phase III enrollment materially de-risk the alixorexton program's regulatory pathway and can provide exclusivity and development incentives. Successful execution would add a new, protected revenue stream and extend long-term growth optionality.
Bears Say
Sharp Increase In Leverage After AcquisitionA material step-up in debt to ~$1.58B increases interest, covenant and refinancing risk and reduces financial flexibility. Higher leverage constrains the company's ability to fund development or absorb shocks, making execution and cash conversion more critical over the coming months.
Weakened Cash-flow Quality And MomentumSubstantial decline in free-cash-flow momentum and lower OCF-to-net-income conversion suggest working-capital pressure or one-offs. With elevated debt, deteriorating cash conversion reduces capacity to pay down leverage and fund pipeline investments without pressuring liquidity.
Elevated R&D/SG&A And Near-term Margin PressureRising R&D and SG&A from program scaling and acquisition integration, plus inventory step-up and widening gross-to-net, compress near-term margins. Sustained higher operating cost base can weigh on adjusted profitability and cash flow while the company executes launches and trials.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $53.69 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $8.81B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Jul 29, 2026 which is in 33 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on May 05, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.146.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is -0.02.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 166,675,810 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went up 6.087%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.20 (45.38% Upside)
$50.20 (45.38% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $687.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.89%
12-Months-Change
Fundamentals
Return on Equity
8.82%
Trailing 12-Months
Asset Growth
104.52%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum, sizable year-over-year revenue growth (+38% for proprietary products), an encouraging early LUMRYZ launch with meaningful sales and patient growth, a material adjusted EBITDA beat, and clear pipeline progress with Phase III initiation and multiple new programs underway. Offsetting factors include a GAAP net loss and negative GAAP EBITDA in the quarter, elevated R&D and SG&A as programs scale and integration costs are realized, increased leverage and near-term margin pressure from inventory step-up and widening gross-to-net. On balance, the positives (revenue growth, LUMRYZ contribution, adjusted EBITDA beat, improved purchase price accounting and an expanding orexin pipeline) meaningfully outweigh the near-term financial and execution headwinds.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$50.20
▲(45.38% Upside)
Technical Analysis
Ownership Overview
1.43% Insiders
26.17% Mutual Funds
29.61% Other Institutional Investors
11.73% Public Companies and
Individual Investors